SUMMARY The acute hemodynamic effects of dobutamine and nitroprusside were compared in 19 patients with low output cardiac failure. At dosage levels yielding similar increases in cardiac index (12 patients) , nitroprusside resulted in significantly lower arterial systolic and wedge pressures and did not increase heart rate suggesting advantages over dobutamine when reduction in myocardial oxygen requirement or pulmonary congestion is a major goal. Systemic arterial mean and diastolic pressures were minimally changed with dobutamine, but fell significantly with nitroprusside suggesting advantages of dobutamine over nitroprusside in patients PHARMACOLOGIC EFFORTS to improve cardiac function in patients with acute or chronic heart failure are practiced daily as evidenced by the widespread use of digitalis and diuretics. Although most patients respond satisfactorily to these agents, there remain some patients who are chronically disabled or develop acute deterioration in ventricular function as the result of myocardial infarction, sudden valvular insufficiency or cardiac surgical procedures. In such patients, additional pharmacologic support of cardiac function may be required to temporarily tide the patient over during a crisis or to buy time for diagnostic studies and/or definitive therapy. Over the past few years, intravenous inotropic and vasodilator agents have been used successfully in the temporary management of such patients while more recently oral vasodilator agents have shown promise as a means of obtaining long-term clinical and hemodynamic benefit.
Among the newer drugs, dobutamine, a beta adrenergic agent, has received attention because its potent inotropic activity is associated with minimal direct vascular effects. Conversely, nitroprusside, a direct vasodilator which lacks direct cardiac effects, is presently being used widely in the management of such patients. Previous studies with dobutaminet and nitroprusside4-6 have shown that both agents result in significant improvement in cardiac output and left ventricular performance when given to patients with severe low output cardiac failure. However, since the two drugs differ basically in their mode of action, they may also differ significantly with regard to other hemodynamic effects. Accordingly, we have compared the acute hemodynamic effects of dobutamine infusion to those of sodium nitroprusside infusion in a group of 19 patients with chronic low output cardiac failure. By using each patient as his own control and by titrating dosages of each agent to achieve 918 where hypotension could limit coronary blood flow or perfusion of other vital organs. Reduction in pulmonary arteriolar resistance occurred only with nitroprusside. Arterial hypoxemia developed in three patients during nitroprusside infusion suggesting the possibility of increased right-to-left intrapulmonary shunting resulting from a direct vasodilating effect of nitroprusside on pulmonary arteriole smooth muscle. Although both inotropic and vasodilator drugs can result in hemodynamic improvement when administered to patients with chronic low output cardiac failure, significant differences of potential clinical importance exist between these two modes of therapy. similar and physiologically significant increases in cardiac output, the two drugs have been shown to exert different hemodynamic effects of potential clinical importance.
Methods and Materials The patients studied were all males, hospitalized for symptoms of chronic low output cardiac failure (NYHA class III or IV) in spite of treatment with digitalis and diuretics. Fourteen patients had arteriosclerotic heart disease and five had primary myocardial disease. Nine patients had some degree of mitral regurgitation, but in none was the valvular lesion considered to be the major cause of heart failure. Ages ranged from 33 to 71 years and averaged 57 years. Two patients were in atrial fibrillation and the remainder were in normal sinus rhythm. Informed consent was obtained from each patient prior to the study.
On the morning of the study, each patient was brought to the special hemodynamic research unit in the fasting state without premedication. A #7F thermal dilution Swan-Ganz catheter was inserted in an antecubital vein and advanced under fluoroscopic control until the catheter tip was situated in the right or left pulmonary artery. The tip was positioned to yield a reliable wedge pressure (WP) waveform when the balloon was inflated and pulmonary artery systolic (PASP) and diastolic (PADP) pressure waveform when the-balloon was deflated. Right atrial pressure (RAP) was measured from the proximal lumen. Cardiac output (CO) was determined by averaging three or more thermal dilution curves obtained by injecting 10 cc of 0°C saline into the right atrium. A Model 9500 Edwards Laboratory cardiac output computer was used to give on-line readout of cardiac output. Arterial systolic (ASP) and diastolic (ADP) pressures were measured from an indwelling catheter in the radial or brachial artery. All pressures were obtained from Statham 23Db transducers leveled at the midchest position. Mean pulmonary (MPAP) and mean systemic arterial (MAP) pressures were determined by electrical damping. Heart rate (HR) was determined from a standard ECG lead which was monitored continuously. Pressures and ECGs were recorded on a multichannel photographic recorder run at various paper speeds. Arterial (AO2) and pulmonary (PAO2) oxygen DOBUTAMINE AND NITROPRUSSIDE IN LOW OUTPUT FAILURE/Berkowitz et al. saturations were determined by oximetry using an American Optical oximeter.
Calculations were made using the following formulae:
Cardiac index (CI) = CO/body surface area; Stroke index (SI) = CI/HR; Left ventricular stroke work index (LVSWI) = (MAP -WP) X SI X 13.6/1000; Systemic arteriolar resistance (SAR) = (MAP -RAP/CO; Pulmonary arteriolar resistance (PAR) = (MPAP -WP)/CO. At the onset of the study, control measurements were obtained and were repeated after 15 minutes to insure hemodynamic stability. When a steady state had been achieved, either dobutamine or nitroprusside was infused at a constant rate using an IVAC constant infusion pump. Repeat measurements were made and dosages adjusted at 15 minute intervals once a new steady state was reached. When measurements had been obtained at one or more dosages, the first drug was stopped and the patient was allowed to return to control status. After 30 minutes, a second set of control measurements was obtained, the second drug was infused and measurements were obtained as with the first drug.
Since improved cardiac output is a major objective when these drugs are given to patients with low output cardiac failure we thought it important that the two drugs be compared under conditions where increases in cardiac output were similar. Our goal was to titrate each agent to achieve a cardiac output 50% above the initial control value, or if this was not possible, to achieve similar increases in cardiac output. Table I shows CI during both control periods obtained before infusion of either drug (columns I and 2), between the two drug infusions (column 3), and during infusion of each drug at the various dosages studied. In the twelve patients listed at the top, it was possible with both agents to titrate the drug dosages to achieve a cardiac index which agreed by 0.3 L/min/m2. Taken as percent change from control, CI in-creased from 11% to 100% (mean 48%) during dobutamine infusion and from 12% to 100% (mean 46%) during infusion of nitroprusside. In the seven patients listed at the bottom, the lowest cardiac index achieved during dobutamine infusion was at least 0.6 L/min/m2 above the highest CI achieved during infusion of nitroprusside. The increases ranged from 57% to 131% (mean 88%) during dobutamine infusion and from 19% to 54% (mean 31%) during nitroprusside infusion. Although these seven patients were clinically and hemodynamically similar to the other 12 patients, we have chosen to exclude them from further analysis in order to compare the two drugs under conditions when cardiac outputs were similarly increased.
Results
Complete hemodynamic data during control, dobutamine and nitroprusside infusion are listed in table 2 for the 12 patients whose CI during both agents agreed within 0.3 L/min/m2. The single control value listed was that which was obtained just prior to infusion of the first agent. Three patients received dobutamine before nitroprusside and nine patients received nitroprusside before dobutamine. The mean dosages (+ SEM) of each drug were 8.0 ± 0.9
Ag/kg/min for dobutamine and 61.5 ± 3.5 ,ug/min for nitroprusside. ASP was 123 ± 7 mm Hg during control, increased significantly to 141 i 9 mm Hg with dobutamine and fell moderately to 113 i 6 mm Hg during nitroprusside infusion. MAP, which averaged 88 ± 4 mm Hg at control, increased slightly to 95 ± 4 mm Hg during dobutamine, but was significantly decreased to 76 ± 3 mm Hg with nitroprusside. ADP, which was essentially unchanged during infusion of dobutamine (72 ± 3 to 73 ± 4 mm Hg), likewise fell significantly during nitroprusside infusion averaging 60 ± 3 mm Hg. Each of these pressures was significantly (P < 0.001) lower during nitroprusside than during dobutamine.
Pulmonary Artery and Right Atrial Pressures ( fig. 2) PASP, MPAP and PADP averaged 60 ± 2 mm Hg, 41 1 mm Hg and 31 ± I mm Hg, respectively, during control CI averaged 1.7 ± 0.1 L/min/m2 during control and was under 2.0 L/min/m2 in 11 of the 12 patients. By design, CI was increased to a similar extent during infusion of both drugs averaging 2.4 ± 0.1 with each. Taken as percent change from control, CI was increased from 11% to 100% (mean 48%) during dobutamine infusion and from 12% to 100% (mean 46%) during infusion of nitroprusside.
Heart Rate HR averaged 86 ± 5 beats/min during control, increased slightly during dobutamine to an average of 92 ± 5 beats/ min. This was significantly higher than HR during nitroprusside which remained at 86 ± 5 beats/min (P < 0.001).
C DB NP FIGURE 1. Systemic arterial pressures (mean ± SEM) during control (C), dobutamine infusion (DB) and nitroprusside infusion (NP) for the 12 patients having similar increases in cardiac output during infusion of both agents. All pressures were lower during nitroprusside infusion than during dobutamine. and increased to 70 ± 4 mm Hg, 46 ± 2 mm Hg and 32 ± I mm Hg during infusion of dobutamine. Each of these pressures was significantly lower with nitroprusside averaging 50 + 2 mm Hg, 33± I+ mm Hg and 24 + 1 mm Hg (P < 0.001). Wedge pressure, which averaged 28 ± 2 mm Hg during control, fell slightly during dobutamine infusion to 26 ± 2 mm Hg and was significantly lower during nitroprusside infusion averaging 20 ± 2 mm Hg (P < 0.001). Right atrial pressure fell from 11 ± 1 mm Hg to 10 ± 1 mm Hg with dobutamine and to 7 ± 1 mm Hg with nitroprusside (P < 0.001). LVSWI increased from 16 ± 2 g-m/m2 to 26 ± 2 g-m/m2 with dobutamine which was not significantly different from nitroprusside averaging 24 ± 2 g-m/m2. Hg/L/min during control and was essentially unchanged with dobutamine averaging 4.7 ± 0.5 mm Hg/L/min. During nitroprusside infusion, PAR fell to 3.2 i 0.2 mm Hg/L/min which was significantly lower than with dobutamine (P < 0.001).
Oxygen Saturation AO2 averaged 94 ± 1% during control, 93 + 1% during dobutamine and 91 ± 1% during nitroprusside. This small difference in AO2 between dobutamine and nitroprusside was significant (P < 0.02). PAO, was markedly reduced during control averaging 49 2% and increased significantly during infusion of both dobutamine and nitroprusside, averaging 59 ± 2% and 60 + 2% respectively (NS). AVO2 difference was reduced from 46 ± 2% during control to 34 ± 2% during dobutamine infusion and was not significantly different during nitroprusside infusion averaging 31 ± 2%.
Adverse Effects
In one patient with severe heart failure due to ischemic heart disease, hypotension (MAP from 96 mm Hg to 64 mm Hg) occurred during infusion of nitroprusside at a dosage of 110 ,ug/min. At this time, WP had fallen from 31 mm Hg to 24 mm Hg while CI had increased from 1.3 L/min/m2 to 2.4 L/min/m2. Twenty-five minutes after nitroprusside had been discontinued, MAP had fallen further to 54 mm Hg and WP was 16 mm Hg. Because the patient was somewhat lethargic and had developed ventricular premature beats, norepinephrine infusion was instituted. Arterial pressure stabilized promptly and the infusion was discontinued an hour later without return of hypotension or other sequel. Since this patient did not receive dobutamine, he has not been included among the 19 patients previously discussed. None of the remaining 19 patients showed any adverse effects related to the study and in many, subjective improvement was noted during infusion of both agents. Although some patients appeared to have an increased frequency of ventricular ectopic beats during infusion of dobutamine, no patient developed a serious or life-threatening arrhythmia during infusion of either agent.
Discussion
The present study was undertaken to compare the acute hemodynamic effects of a pure inotropic agent, dobutamine, to those of a pure vasodilator agent, nitroprusside, in patients with stable, chronic low output cardiac failure. In 12 patients, it was possible to make the comparison with the cardiac output having been increased by essentially the same amount with each drug. Although the seven patients in whom this was not possible have been excluded from further analysis, they illustrate the fact that some patients who fail to respond adequately to vasodilator therapy may still respond well to an inotropic agent.
Both drugs resulted in a reduction of SAR. Reduction in SAR during dobutamine could be ascribed to withdrawal of compensatory vasoconstriction7 and/or opening of latent vessels (recruitment) due to the increased systolic pressure. A direct peripheral vasodilator effect of dobutamine, although demonstrable in the laboratory animal, appears to be small relative to its inotropic activity.8-10 During nitroprusside infusion, SAR was reduced more than during dobutamine and this difference can be ascribed to the potent vasodilator effects of nitroprusside1l and suggests that dobutamine might be preferred over nitroprusside for augmentation of cardiac output in hypotensive patients or in patients with pre-existing vascular disease where blood flow to vital organs may be largely dependent upon arterial pressure.
The effects of dobutamine and nitroprusside on heart rate also differed. Moderate increases in heart rate occurred in most patients during infusion of dobutamine. Although dobutamine has been offered as an inotropic catecholamine lacking significant chronotropic and arrhythmogenic properties,8 studies by our group' 12 14 and others2 have demonstrated dobutamine to consistently exert chronotropic activity when administered to patients with heart failure. Tachycardia during dobutamine infusion may thus limit its usefulness in some patients. In contrast, nitroprusside, which lacks direct chronotropic activity, has a variable effect on heart rate in patients with heart failure.4'5 When heart rate increases during nitroprusside therapy, it is probably the result of compensatory reflexes" and suggests inadequate ventricular filling and/or excessive hypotension. '5 Dobutamine was less effective than nitroprusside in lowering the elevated wedge pressure. In the dog, dobutamine causes venoconstriction,'6 an effect which would tend to increase wedge pressure. In those patients whose wedge pressures fell significantly with dobutamine, the mechanism was most likely improved systolic emptying and a more favorable pressure-volume relationship at the onset of ventricular filling. ' Temporary support for low output states may be required in patients with ischemic heart disease and attention must be paid to the relative effects of therapeutic agents on the relationship between myocardial oxygen delivery and requirement. Our data suggest that dobutamine, which increased heart rate and arterial pressure and is known to exert direct inotropic effects," 8 probably increased myocardial oxygen requirements while nitroprusside, which did not alter heart rate, lowered arterial pressure and does not possess direct inotropic activity," probably reduced oxygen requirements. Nitroprusside might therefore be favored in patients with ischemic heart disease. However, changes in coronary blood flow and its distribution must also be considered and may not be predictable from hemodynamic measurements.
Animal studies20' 21 have differing conclusions with regard to the effects dobutamine has on myocardial ischemia. In patients with evolving acute myocardial infarction (AMI), Gillespie et al.22 found no evidence of increased infarct size during infusion of dobutamine. Controversy also exists regarding the net effect of nitroprusside on the balance between myocardial oxygen supply and demand. In animals, nitroprusside has been shown to both increase and reduce experimental ischemia.22 25 Clinical studies have likewise yielded conflicting results. Armstrong et al.26 studied four patients with AMI and a wedge pressure above 18 mm Hg and found significant reduction in the elevated ST segments during nitroprusside. However, in five patients whose wedge pressures were between 11 and 14 mm Hg, ST-segment elevation was minimally affected during infusion of nitroprusside. Awan et al.27 similarly evaluated 12 patients with AMI and reported reduction in ST-segment elevation suggesting a beneficial effect of nitroprusside on myocardial ischemia. Magnusson et al.28 using early serum CPK levels to predict infarct size, studied four patients with AMI infused with nitroprusside. Subsequent CPK values suggested a larger infarct size than had been predicted from CPK values determined prior to the infusion. In spite of these potential hazards, nitroprusside has often been effective in reversing the clinical manifestations of myocardial ischemia.29 In the absence of hypotension, vasodilator therapy would appear to be a rational first choice for patients with severe heart failure and ischemic heart disease. Since some patients fail to respond satisfactorily to vasodilators and yet respond well to inotropic agents, the ultimate choice of therapy must be determined by the clinical and hemodynamic responses to the drug. It should be noted that although 14 of our 19 patients were considered to have ischemic heart disease, we did not observe clinical or electrocardiographic evidence of increased myocardial ischemia during infusion of either agent. A final comment should be made regarding the effects of dobutamine and nitroprusside on pulmonary vascular resistance and gas exchange. With dobutamine, pulmonary arteriolar resistance was unchanged while during infusion of nitroprusside pulmonary arteriolar resistance fell from 4.6 to 3.2 mm Hg/L/min. Reactive pulmonary arteriolar constriction may occur in patients with left heart failure who have arterial hypoxemia secondary to pulmonary venous congestion.30 Under these circumstances, reduction in left ventricular filling pressure and/or oxygen therapy should be associated with clinical improvement. It seems unlikely that the fall in PAR during nitroprusside infusion was due to this mechanism in our patients since control arterial 02 saturation was above 90% in each of the 10 patients in whom it was measured. A direct dilating action of nitroprusside on pulmonary arteriole smooth muscle'1 seems a better explanation. Such an effect might be advantageous in patients with combined right and left ventricular failure. In patients with unequal ventilation, regional pulmonary vasoconstriction may be important in preventing perfusion of nonventilated areas in order to limit right-to-left shunting. Worsening of the ventilation-perfusion relationship with increased right-to-left shunting has been reported during nitroprusside infusion in patients with congestive heart failure2' 32 treo and following cardiac surgery. In three of our patients, arterial oxygen saturation fell below 90% during nitroprusside infusion. Although the clinical significance of increased right-to-left intrapulmonary shunting during nitroprusside therapy for heart failure has yet to be determined, the potential danger of causing arterial hypoxemia in patients with severe pulmonary disease should be considered. of dobutamine on regional myocardial blood flow and ventricular performance during acute and chronic myocardial ischemia in dogs. Nineteen patients with OCPD have been identified in a five year period. Unexplained fatigue, dyspnea and chest pain was the uniform pattern of presentation. Eleven have undergone pericardiectomy resulting in a dramatic symptomatic improvement in all. Each demonstrated gross and/or microscopic evidence of pericardial disease. Recatheterization with volume infusion in five patients following pericardiectomy has revealed return to normal or near normal hemodynamics. This study describes the method for diagnosis of OCPD and recommends pericardiectomy for the management of disabling symptoms.
without provocative maneuvers, the patients described herein all had pericardial constriction demonstrable only by the technique of rapid intravascular volume expansion. We have chosen the designation occult constrictive pericardial disease (OCPD) for this entity.
Patient Population Nineteen patients, 12 males and 7 females, ages 18-69, constitute those found to have OCPD. All patients had a complete history and physical examination, chest X-ray, resting electrocardiogram, and precatheterization cardiac fluoroscopy.
Characteristics of the patient population are listed in table 1. All had disabling symptoms of fatigue, dyspnea and chest pain for 4-60 months prior to diagnosis. Twelve patients had a clear history of remote acute pericarditis of which only five had subsequent recurrent pericarditis. No patient had active pericarditis at the time of diagnostic study. Ten patients had chest X-ray abnormalities, two having globular 924 CIRCULATION
